Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors von Terheyden, P., Weishaupt, C., Heinzerling, L., Klinkhardt, U., Krauss, J., Mohr, P., Kiecker, F., Becker, J.C., Dähling (Submitter, A., Döner, F., Heidenreich, R., Scheel, B., Schönborn-Kellenberger, O., Seibel, T., Gnad-Vogt, U.

Volltext

1305TiPPhase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors von Terheyden, P, Weishaupt, C, Heinzerling, L, Klinkhardt, U, Krauss, J, Mohr, P, Kiecker, F, Becker, J C, Dähling (Submitter, A, Döner, F, Heidenreich, R, Scheel, B, Schönborn-Kellenberger, O, Seibel, T, Gnad-Vogt, U

Volltext